Qiagen Q1 Revenues Flat, Beat Wall Street Expectation | GenomeWeb

This article has been updated from a previous version to include comments made by Qiagen CEO Peer Schatz during an earnings call.

NEW YORK (GenomeWeb) – Qiagen said after the close of the market Wednesday that its first quarter revenues were flat year over year, but the top-line result exceeded analysts' expectations.

For the three months ended March 31, Qiagen reported $298.4 million in revenues, exceeding the Wall Street consensus estimate of $295.8 million. On an adjusted basis and at constant exchange rates (CER), Q1 revenues increased 2 percent year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Sponsored by
Agilent Technologies

In this online seminar, speakers from the Center for Personalized Diagnostics at Penn Medicine will discuss the design and technical validation of a custom next-generation sequencing panel to detect mutations in a wide array of tumor types.